<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063763</url>
  </required_header>
  <id_info>
    <org_study_id>ITP0614</org_study_id>
    <nct_id>NCT02063763</nct_id>
  </id_info>
  <brief_title>TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.</brief_title>
  <acronym>ITP0614</acronym>
  <official_title>Use of TPO-mimetics to Prepare for Splenectomy in Adult Patients With Primary Immune Thrombocytopenia. Brooklyn Observational Retrospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at analyzing the therapeutic activity of TPO-mimetics Eltrombopag and
      Romiplostim as bridge therapy for splenectomy in adult patients with primary immune
      thrombocytopenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult immune primary thrombocytopenia is an autoimmune malignancy characterized by platelet
      destruction and inadequate platelet production. Its incidence is of three cases per 100,000
      people a year, with a prevalence in women in young and older adults.

      Splenectomy is, still today, the therapeutic approach that offers a bigger guarantee of a
      long term response (around 60+70%). Nevertheless, splenectomy may be accompanied by
      peri-operative complications in almost 10% of patients, which in rare cases may be fatal.
      These are normally hemorrhagic complications due to low platelet count. Thus, a previous
      therapy to increase platelets is advisable before any splenectomy.

      In patients who are refractory to corticosteroids and immunoglobulins or when its use is not
      indicated, splenectomy has a potential risk of more complications. Since the last few years,
      we count with TPO-mimetic drugs, specific for c-MPL receptor, able to stimulate platelet
      production, such as romiplostim and eltrombopag.

      Nowadays, TPO-mimetics are allowed in Italy when patients refuse splenectomy or when
      splenectomy is not contraindicated, but being ITP with a low platelet count (&lt; 20-50.000/mmc)
      a potential contraindication to splenectomy due to hemorrhagic events, these drugs should be
      considered. Nevertheless, there are no data on therapeutic risks and safety of these agents
      when used for this indication. The aim of the present study is to verify, on an Italian
      national scale, the frequency of use, its impact and the safety profile.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients responding to TPO-mimetics</measure>
    <time_frame>Six months.</time_frame>
    <description>According to platelet count and presence or absence of hemorrhagic events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients on TPO-mimetics eltrombopag and romiplostim as bridge therapy before splenectomy.</measure>
    <time_frame>Six months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and ways of administration.</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hemorrhagic events.</measure>
    <time_frame>At thirty days from splenectomy.</time_frame>
    <description>Number and seriousness of hemorrhagic, thrombotic and infectious events at 30 days from splenectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of toxicity.</measure>
    <time_frame>Six months</time_frame>
    <description>NCI CTCAE v. 4.0</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Adult Patients</condition>
  <condition>Immune Primary Thrombocytopenia</condition>
  <condition>Splenectomy</condition>
  <condition>TPO-mimetics</condition>
  <eligibility>
    <study_pop>
      <textblock>
        ITP adult patients having undergone splenectomy after a bridge therapy with eltrombopag or
        romiplostim.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent or chronic ITP in symtomatic phase.

          -  18 years of age or older.

          -  Indication for splenectomy due to refractory response to a previous therapy.

          -  Have used eltrombopag or romiplostim to increase platelet count before splenectomy.

          -  Have undergone splenectomy.

        Exclusion Criteria:

          -  No informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Zaja, Pr.</last_name>
    <role>Study Chair</role>
    <affiliation>Clinica Ematologica, DISM, Azienda Ospedaliera Universitaria S. M. Misericordia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enrico Crea</last_name>
    <email>e.crea@gimema.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>U.O.C di Ematologia P.O. &quot;S.Giuseppe Moscati&quot;</name>
      <address>
        <city>Aversa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Caparrotti</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Caparrotti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Esposito</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia Ospedale &quot; Mons. Dimiccoli&quot;</name>
      <address>
        <city>Barletta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Tarantini</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Tarantini</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caterina Buquicchio</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico di Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Bosi</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Bosi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina Carrai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margherita Giannoccaro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa) - Medicina Generale - Sezione di Ematologia - Ospedale Versilia USL 12 Toscana</name>
      <address>
        <city>Lido di Camaiore</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Lambelet</last_name>
    </contact>
    <investigator>
      <last_name>Paola Lambelet</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Federico Simonetti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilma Barcellini</last_name>
    </contact>
    <investigator>
      <last_name>Wilma Barcellini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda &quot; Ca Granda&quot; - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Cantoni</last_name>
    </contact>
    <investigator>
      <last_name>Silvia Cantoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Trapianto di Midollo Ist. Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Di Nicola</last_name>
    </contact>
    <investigator>
      <last_name>Massimo Di Nicola</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michele Magni</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;S.Gerardo&quot;</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Carpenedo</last_name>
    </contact>
    <investigator>
      <last_name>Monica Carpenedo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronica Coccini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano</last_name>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariangela Greco</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gabriella Mazzucconi</last_name>
    </contact>
    <investigator>
      <last_name>Maria Gabriella Mazzucconi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria - Terni S.C Oncoematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Maria Liberati</last_name>
    </contact>
    <investigator>
      <last_name>Anna Maria Liberati</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angelo Genna</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Policlinico Universitario</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Zaja</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Zaja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dino Veneri</last_name>
    </contact>
    <investigator>
      <last_name>Dino Veneri</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Pizzolo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult patients</keyword>
  <keyword>Immune primary thrombocytopenia</keyword>
  <keyword>Splenectomy</keyword>
  <keyword>TPO-mimetics</keyword>
  <keyword>Eltrombopag</keyword>
  <keyword>Romiplostim</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

